GenFleet Therapeutics, focusing on oncology, autoimmune, and inflammatory diseases, passed the listing hearing of the Hong Kong Stock Exchange at the end of last month. It is expected to be listed in Hong Kong soon, with CITIC Securities as its sole sponsor.

GenFleet Therapeutics is applying for listing under Chapter 18A and has not yet recorded a profit. For the first four months ending April 2025, the company recorded revenue of RMB82.149 million, compared to no revenue in the same period last year, with a net loss of RMB66.624 million, narrowed from RMB405 million in the same period last year.